Cardiff Oncology Files 8-K with Key Updates

Ticker: CRDF · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1213037

Cardiff Oncology, Inc. 8-K Filing Summary
FieldDetail
CompanyCardiff Oncology, Inc. (CRDF)
Form Type8-K
Filed DateDec 10, 2024
Risk Levelmedium
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, corporate-filing

TL;DR

Cardiff Oncology dropped an 8-K on 12/10 - check it for Reg FD, other events, and financials.

AI Summary

Cardiff Oncology, Inc. filed an 8-K on December 10, 2024, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Trovagene, Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing provides crucial updates and disclosures for investors regarding Cardiff Oncology's corporate activities and financial reporting.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant corporate news, but this specific filing appears to be a routine update rather than a major event, warranting a medium risk assessment.

Key Numbers

  • 001-35558 — SEC File Number (Identifies the company's filing history)
  • 27-2004382 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Cardiff Oncology, Inc. (company) — Registrant
  • Trovagene, Inc. (company) — Former company name
  • December 10, 2024 (date) — Date of report
  • San Diego, California (location) — Principal executive offices

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure but does not detail the specific information released under this item within the provided text.

What are the 'Other Events' reported by Cardiff Oncology?

The filing lists 'Other Events' as an item but does not specify the nature of these events in the provided text.

What financial statements and exhibits are included in this filing?

The filing mentions 'Financial Statements and Exhibits' as an item, but the specific contents are not detailed in the provided text.

When was Cardiff Oncology, Inc. previously known as?

Cardiff Oncology, Inc. was formerly known as Trovagene, Inc., with previous name changes from TrovaGene Inc. and XENOMICS INC.

Where are Cardiff Oncology's principal executive offices located?

Cardiff Oncology's principal executive offices are located at 11055 Flintkote Avenue, San Diego, California, 92121.

Filing Stats: 661 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-12-10 06:02:28

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 10, 2024, Cardiff Oncology, Inc. (the "Company") plans to present in a conference call presentation materials related to the announcement of positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). A copy of the presentation materials is furnished as Exhibit 99.1 to this Form 8-K. The information in this report, including the press release furnished as Exhibit 99.1 hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as "forward-looking statements" that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.

01 Other Events

Item 8.01 Other Events. On December 10, 2024, the Company issued a press release (the "Press Release") announcing positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). A copy of the press release is attached as Exhibit 99.2 hereto. The information in the Press Release, except for the information set forth in the second paragraph of the Press Release containing a quote by Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of the Company and the seventh paragraph of the Press Release containing a quote by Mark Erlander, Chief Executive Officer of the Company, is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits (d) Exhibits. 99.1 Cardiff Oncology, Inc. Corporate Presentation 99.2 Press Release of Cardiff Oncology, Inc. dated December 10, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARDIFF ONCOLOGY, INC. Date: December 10, 2024 By: /s/ Mark Erlander Mark Erlander Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.